Showing 321-328 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| JDRF T1D Coordinating Center | Jaeb Center for Health Research | Judy Sibayan | Transportfolio | 01-August-2019 to 31-August-2027 | $2.914.531,01 |
| Identification of novel targets to increase human beta cell proliferation | The Regents of the University of California, San Francisco | Gregory Ku | Cures | 01-December-2020 to 30-June-2026 | $975.000,00 |
| Defining the cell surface glycoproteome and glycome of human islets to enable single cell analysis of human β-cells | The Medical College of Wisconsin Inc. | John Corbett | Cures | 01-October-2022 to 30-June-2026 | $750.000,00 |
| Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Patients | Mayo Clinic | Adrian Vella | Improving Lives | 01-October-2019 to 31-March-2025 | $437.405,39 |
| Evaluation of the safety, tolerability, and general response to Lactobacillus johnsonii N6.2 in children and adolescents with T1D | University of Florida | Graciela Lorca | Cures | 01-September-2019 to 31-August-2026 | $355.941,78 |
| Early immune and beta cell monitoring predicts treatment response | Benaroya Research Institute at Virginia Mason | S. Alice Long | Cures | 01-August-2019 to 31-July-2025 | $2.499.814,79 |
| Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Mitigate Diabetic Ketoacidosis Risk? | University of Texas Health Science Center at San Antonio | Muhammad Abdul-Ghani | Improving Lives | 01-June-2019 to 30-September-2025 | $1.573.835,31 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-March-2026 | $1.808.522,70 |